Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront
Eli Lilly is acquiring AtaiBeckley, a developer of psychedelic treatments for mental health conditions.
Eli Lilly is acquiring AtaiBeckley, a developer of psychedelic treatments for mental health conditions.